JGGDR
JGP Global Gestao de Recursos Portfolio holdings
AUM
$204M
1-Year Return
109.69%
This Quarter Return
+20.18%
1 Year Return
+109.69%
3 Year Return
+285.93%
5 Year Return
+345.7%
10 Year Return
+378.07%
AUM
$51.1M
AUM Growth
-$27.7M
(-35%)
Cap. Flow
-$28M
Cap. Flow
% of AUM
-54.76%
Top 10 Holdings %
Top 10 Hldgs %
78.6%
Holding
52
New
10
Increased
19
Reduced
8
Closed
12
Top Buys
| 1 |
NGD
New Gold Inc
NGD
|
$14.3M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$2.65M |
| 3 |
Itaú Unibanco
ITUB
|
$1.32M |
| 4 |
Insmed
INSM
|
$447K |
| 5 |
Summit Therapeutics
SMMT
|
$374K |
Top Sells
| 1 |
Nu Holdings
NU
|
$15.8M |
| 2 |
StoneCo
STNE
|
$10.6M |
| 3 |
S&P Global
SPGI
|
$2.23M |
| 4 |
Incyte
INCY
|
$450K |
| 5 |
Exxon Mobil
XOM
|
$353K |
Sector Composition
| 1 | Healthcare | 42.57% |
| 2 | Materials | 30.33% |
| 3 | Technology | 23.91% |
| 4 | Financials | 2.58% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Revolution Medicines
RVMD
$7.24B
| $349K | 0.68% |
+7,706
| New | +$349K |
|
27
Cigna
CI
$80.7B
| $316K | 0.62% |
912
+276
| +43% | +$95.6K |
|
28
VanEck Gold Miners ETF
GDX
$19.3B
| $313K | 0.61% |
+7,871
| New | +$313K |
|
29
Alamos Gold
AGI
$13.3B
| $308K | 0.6% |
15,452
| – | – |
|
30
Boston Scientific
BSX
$160B
| $302K | 0.59% |
+3,608
| New | +$302K |
|
31
Kymera Therapeutics
KYMR
$2.97B
| $284K | 0.55% |
+5,992
| New | +$284K |
|
32
Novo Nordisk
NVO
$251B
| $259K | 0.5% |
2,171
+522
| +32% | +$62.2K |
|
33
HCA Healthcare
HCA
$97.5B
| $237K | 0.46% |
+583
| New | +$237K |
|
34
Molina Healthcare
MOH
$9.17B
| $209K | 0.41% |
608
-161
| -21% | -$55.5K |
|
|
BPMC
35
DELISTED
Blueprint Medicines
BPMC
| $204K | 0.4% |
+2,204
| New | +$204K |
|
36
Becton Dickinson
BDX
$54.6B
| $203K | 0.4% |
+841
| New | +$203K |
|
37
AbCellera Biologics
ABCL
$1.2B
| $58.8K | 0.11% |
22,598
+4,819
| +27% | +$12.5K |
|
38
Kodiak Sciences
KOD
$448M
| $33.8K | 0.07% |
12,950
-2,007
| -13% | -$5.24K |
|
39
Cerus
CERS
$253M
| $27.8K | 0.05% |
15,963
+1,424
| +10% | +$2.48K |
|
40
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-10,865
| Closed | -$67.1K |
|
41
BioMarin Pharmaceuticals
BMRN
$10.9B
| – | – |
-4,213
| Closed | -$347K |
|
|
42
Nu Holdings
NU
$72B
| – | – |
-1,229,300
| Closed | -$15.8M |
|
43
Roivant Sciences
ROIV
$8.7B
| – | – |
-10,036
| Closed | -$106K |
|
44
Sigma Lithium
SGML
$662M
| – | – |
0
| – | – |
|
|
45
S&P Global
SPGI
$165B
| – | – |
-5,000
| Closed | -$2.23M |
|
|
46
Exxon Mobil
XOM
$481B
| – | – |
-3,066
| Closed | -$353K |
|
|
OIBR.C
47
DELISTED
OI S.A. American Depositary Shares, each representing five shares of common stock
OIBR.C
| – | – |
-575,000
| Closed | -$1.5K |
|